60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP Real Time Price USDRecent trades of SXTP by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SXTP's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects Sep. 05, 2023
-
Patent Title: Methods for the treatment and prevention of lung infections caused by gram-positive bacteria, fungus, or virus by administration of tafenoquine Apr. 25, 2023
-
Patent Title: Dosing regimens of celgosivir for the treatment of dengue Jan. 11, 2022
-
Patent Title: Dosing regimens of celgosivir for the prevention of dengue May. 11, 2021
-
Patent Title: Regimens of tafenoquine for prevention of malaria in malaria-naive subjects Jan. 12, 2021
-
Patent Title: Dosing regiments of celgosivir for the treatment of dengue Dec. 31, 2019
-
Patent Title: Regimens of tafenoquine for prevention of malaria in malaria-naive subjects Jul. 09, 2019
-
Patent Title: Dosing regimens of celgosivir for the treatment of dengue Sep. 19, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SXTP in WallStreetBets Daily Discussion
Recent insights relating to SXTP
Recent picks made for SXTP stock on CNBC
ETFs with the largest estimated holdings in SXTP
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SXTP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.